Statin intervention does not slow early-intermediate stage AMD progression

Area of Science:

• Ophthalmology
• Cardiovascular Medicine
• Pharmacology

Background:

• Emerging evidence suggests statins may protect against dry age-related macular degeneration (AMD) progression.
• However, clinical data on statin efficacy for early-intermediate AMD remains inconclusive.

Purpose of the Study:

• To evaluate the effect of statin intervention on the progression of early-intermediate stage non-neovascular (dry) AMD.
• To determine if vascular comorbidities influence the efficacy of statins in AMD management.

Main Methods:

• Retrospective review of 10,026 patient encounters over 10 years (2009-2019).
• Analysis of 1579 patients diagnosed with early-intermediate AMD, noting vascular comorbidities and statin use.
• Statistical analysis using hazard ratios (HR) and confidence intervals (CI).

Main Results:

• 68% of early-intermediate AMD patients with vascular comorbidities received statin intervention.
• Statin use did not significantly alter AMD progression, regardless of vascular comorbidity (HR = 0.97, 95% CI = 0.73-1.28, p=0.82).
• Early-intermediate AMD patients with vascular comorbidities were not at increased risk for AMD progression.

Conclusions:

• Findings do not support the prophylactic use of statins to slow or prevent early-intermediate AMD progression.
• Statin intervention for LDL cholesterol management showed no benefit in this patient cohort.